Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for August 04, 2010 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Clinical Pharmacology Study Group (CPSG) Announces Open Enrollment for Psoriasis; a Chronic Autoimmune Disease
Worcester, MA-based CPSG has many available spaces for participation in clinical trials. 
x-small text small text medium text large text


    WORCESTER, MA, August 04, 2010 /24-7PressRelease/ -- The Clinical Pharmacology Study Group (CPSG) is currently participating in several clinical trials for psoriasis in its Worcester, MA facility.
Psoriasis is a chronic recurring autoimmune disorder. It commonly causes a rapid accumulation of red, scaly patches call psoriatic plaques. Fingernails and toenails are frequently affected and can be an isolated symptom. Psoriasis can occur on the elbow, knees, scalp, genitals, palms of hands and soles of feet. Psoriasis affects people of any age, but it most commonly beings between age 15 and 35. There are five main types of psoriasis: etythrodemic; guttate; inverse; plaque and pustular.

Subjects who enroll in a clinical trial are carefully selected from a list of inclusion and exclusion criteria designed to ensure safety for the subject. Patients' selected to participate in this study are followed by a team of experts in psoriatic arthritis. All study related medications and care are at no cost to the patient. The study group works closely with the patient care provider (PCP), or other specialist, to ensure that all the medical professionals are involved in the treatment of the patient.

"Total patient care is our top priority at CPSG. We educate and treat the individual about the disease and the study. If our medical team concludes that the patient would be better served with an alternative medical treatment, we will help coordinate that care for patients. We pride ourselves in offering superior patient care throughout the study," stated Mary Coughlin, RN and Partner of CPSG.
If you want to learn more or enroll in this local study, please contact the:

Clinical Pharmacology Study Group
UMASS Memorial City Campus
26 Queen Street, Worcester, MA 01610
Phone: 508-755-0201
info@cpsgma.com
http://www.cpsgma.com

About Clinical Pharmacology Study Group
The Clinical Pharmacology Study Group (CPSG) was established in 1989 in Worcester, Massachusetts by Doctor Birbara and Mary Coughlin, RN. The group has been involved in the field of rheumatology study since 1975. The practice has worked with traditional anti-inflammatory medications (NSAIDs) in conjunction with stomach protecting agents. The group has a history of working with Celebrex, Vioxx, Bextra, and other COX II inhibitors. In the late 1990's, we entered the era of biologicals for the treatment of rheumatoid arthritis (RA).

CPSG is continuing to expand work with biologicals in the areas of rheumatoid arthritis, psoriasis, psoriatic arthritis and Chrohn's disease. CPSG is also participating in many new trials for fibromyalgia, osteoarthritis, osteoporosis, gout, and lower back pain.

CONTACT:
Deborah A. Buckley
Phone: +1.978.466-7637
Email: dbuckley@emarketing4us.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Mary Coughlin:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Mary Coughlin
CPSG

Coordinator
26 Queen St.
Worcester, MA
USA 01610
Voice: 508-755-0201
Fax: 508-755-8909
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.